Crowdonomics
This isn’t CBD Life Sciences Inc.’s most recent raise. Reg A+ · Equity · Jun 2026 (Open) is more current.View latest round
CBD Life Sciences Inc.

Reg A+ · Equity · Aug 2022

ClosedReg A+Equity
via the platform · last checked Oct 8, 2026
Raised
$164K / $7.5M max
2% of ceiling
Investors
—
—
Estimated pre-money
$12.2M
—

Financials disclosed in this offering

FY2021 · hover for source
$94K
−$567K
FY2021
RevenueNet income
Metric
FY2021 audited
Income statement
Revenue
$93,553
Cost of goods sold
$45,005
Gross margin
52%
Net income
-$567,085
Balance sheet
Cash
$303,093
Accounts receivable
$120,426
Total assets
$765,877
Long-term debt
$0
Total liabilities
$0
Other
Headcount
5

The fiscal years the issuer disclosed in this offering’s filing, as filed. Full history on the company page.

Deal terms

Est. pre-money$12.2M
Price / share$0.0003
Price / share today$0.09
Shares offered25,000,000,000

Estimated, not stated: $0.0003 × 40,706,241,280 securities outstanding.

$0.0003 as sold; $0.09 after the Apr 2024 split (1:300) (Form 1-A, p. 1).

Down round. Priced 100% below Reg A Offering (2019) (May 2019) on a split-adjusted basis: $0.09 vs $30.00 a share in today's terms.

Offering details

Target—
Max$7,500,000
Min investment—
OpenedAug 18, 2022
Deadline—
ClosedMay 2, 2024
Days active623

Links & provenance

Source: SEC EDGAR
0001683168-22-005902
Last synced Oct 8, 2026

About this data. Raised amounts and investor counts come from the platform listing and may lag or be restated; SEC-reported totals can differ until the next Form 1-Z/C-U. Post-money valuation is computed as pre-money plus amount raised and is shown once the round closes — it is not a traded price. Financial statements are as reported by the issuer. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.